Akari Therapeutics (AKTX) BidaskScore is upgraded to Held

Akari Therapeutics

The BidaskScore of Akari Therapeutics AKTXAKTX shows that the shares of the company are now AKTXStrongly Bought Held by investors.

The BidaskScore of the PharmaceuticalsPharmaceuticals shows that the sector is PharmaceuticalsStrongly Bought Held since January 4.

Here are the BidAskScore of other related companies in the Pharmaceuticals sector:

Akari Therapeutics Plc is a clinical-stage biopharmaceutical companyˌ which focuses in the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5ˌ including paroxysmal nocturnal hemoglobinuriaˌ Guillain Barré syndromeˌ and atypical Hemolytic Uremic Syndrome. The company was founded in 2005 and is headquartered in Londonˌ the United Kingdom.

Akari Therapeutics

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.